Indivior To Participate in STIFEL Healthcare Conference

Slough, UK, and Richmond, VA, November 1, 2023 - Indivior PLC (LSE/NASDAQ: INDV) today announced that it will participate in the following investor event:

·    STIFEL 2023 Healthcare Conference - New York City

Mark Crossley, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, November 14^th and participate in a fireside chat at 8:00 a.m. US EST.  Interested investors should contact their STIFEL representative to schedule a meeting. The fireside chat will be publicly available and can be viewed using the following weblink:

Webcast link

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com

###